A Phase 2 interventional study of Stapokibart injection in Seasonal Allergic Rhinitis (SAR), sponsored by Chengdu Kangnuoxing Biopharma,Inc.. Not yet recruiting at 1 site in China. Open to participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-06-01.
Sponsored by Chengdu Kangnuoxing Biopharma,Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Rhinitis, Allergic, Seasonal with a site in China — 12 open to participants now, 14 under way, 8 of them phase 3. Rhinitis, Allergic, Seasonal · China.
Among the 27 studies in Rhinitis, Allergic, Seasonal with a site in China, this one is the 27th largest by planned enrollment, is one of 6 that started in 2026, is one of 12 in phase 2, reaches primary completion later than 7 of the 13 other live ones, and was the 24th registered.
404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.
Browse Rhinitis, Allergic, Seasonal studies →12 of the 27 studies in Rhinitis, Allergic, Seasonal with a site in China are open now. Recruiting first, the newest first:
Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd. · Sites in China
Ages 18–65
Chengdu Kangnuoxing Biopharma,Inc. · Sites in China
Ages 12–18
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Sites in China
Ages 18–75
Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Sites in China
Ages 18–75
Shanghai Mabgeek Biotech.Co.Ltd · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.
This study: 12 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 13 · Phase 3 11
First in 2017; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15 is below the median of 131 across 366 interventional studies indexed under Rhinitis, Allergic, Seasonal.
Median enrollment 160 across the 27 interventional studies. Of the 12 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 27 have an industry lead sponsor. The 10 most frequent:
Chengdu Kangnuoxing Biopharma,Inc. is the lead sponsor of 6 studies on the registry; 5 are open to participants now.
Chengdu Kangnuoxing Biopharma,Inc. has 2 studies filed under Rhinitis, Allergic, Seasonal — fewer than ten, so there is no comparison to draw.
5 of the studies in Rhinitis, Allergic, Seasonal with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07688772Phase 3Guangdong Hengrui Pharmaceutical Co., LtdA Clinical Study Evaluating the Efficacy and Safety of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis | 2026-12 |
| NCT07678931Phase 3Chengdu Kangnuoxing Biopharma,Inc.Study on the Treatment of Adolescent Patients With Seasonal Allergic Rhinitis | 2026-12 |
| NCT07199257Phase 3Genrix (Shanghai) Biopharmaceutical Co., Ltd.A Study of GR1802 Injection in Patients With Seasonal Allergic Rhinitis. | 2027-05-15 |
| NCT07711262Phase 3Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd.Rupatifen Fumarate Capsules in Patients With Seasonal Allergic Rhinitis | 2027-10 |
| NCT07398859Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Clinical Study on TQH2722 Injection Combined With Background Therapy for Seasonal Allergic Rhinitis | 2026-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 27 studies in Rhinitis, Allergic, Seasonal with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a multicenter, single-arm, open-label, phase II study to evaluate the safety, pharmacokinetics, and immunogenicity of Stapokibart injection in Adolescent Patients with SAR.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Stapokibart injection
subcutaneous injection
Safety parameters
Incidence of adverse events
Time frame: From the signing of ICF(Informed Consent Form) until study completion (or early withdrawal),about 0.5 years
Start is estimated for Jun 2026; primary completion for Oct 2026, 4 months later.
Of 24 phase 2 interventional studies under Rhinitis, Allergic, Seasonal, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 23. This study's planned 4 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Stapokibart
Rhinitis, Allergic, Seasonal →
Chengdu Kangnuoxing Biopharma,Inc.